Dietary and lifestyle modification counseling

BEHAVIORAL2 trials

Sponsors

AstraZeneca

Conditions

Type 2 Diabetes

Phase 2

ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity

TerminatedNCT00263965

AstraZenecaType 2 Diabetes

Start: 2005-08-31End: 2006-07-31Target: 105Updated: 2008-03-17

GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

CompletedNCT00280865

AstraZenecaType 2 Diabetes

Start: 2002-04-30End: 2003-06-30Target: 500Updated: 2006-07-31